Glioblastoma

The PBS subsidises bevacizumab for patients with relapsed or recurrent glioblastoma.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with bevacizumab under the National Health Act 1953, section 100 for patients with relapsed or recurrent glioblastoma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing bevacizumab.

Section 100 arrangements

Bevacizumab is only available for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

You must include the hospital name and provider number on the authority application form. Bevacizumab isn’t PBS subsidised for hospital in-patients.

Applications

Initial treatment

Apply for initial authority approval to prescribe PBS subsidised bevacizumab to treat relapsed or recurrent glioblastoma in writing and either:

All applications must include the completed:

Initial grandfather treatment

For patients who received non-PBS subsidised bevacizumab before 1 August 2019 for relapsed or recurrent glioblastoma, apply for initial grandfather approval in writing and either:

All applications must include the completed:

Continuing treatment

To apply for continuing PBS subsidised bevacizumab to treat relapsed or recurrent glioblastoma, call the PBS Complex Drugs Programs enquiry line.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 August 2019

Was this page useful?
Why?
Why not?

Thank you for your feedback.